Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Michigan Business Tribune.
Press releases published on May 12, 2025
Gaia Reports First Quarter 2025 Results
GlobeNewswire
·
May 12, 2025
BOULDER, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Gaia, Inc. (NASDAQ: GAIA), a conscious media and community company, reported financial results for the first quarter and ended March 31, 2025. Highlights: Fifth consecutive quarter of double digit increases …
Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 12, 2025
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 152, …
Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 12, 2025
– Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2 …
Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 12, 2025
REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven …
TPI Composites, Inc. Announces First Quarter 2025 Earnings Results – Operational Execution and Strategic Initiatives Drive Improved Financial Results; Initiation of Strategic Review
GlobeNewswire
·
May 12, 2025
SCOTTSDALE, Ariz., May 12, 2025 (GLOBE NEWSWIRE) -- TPI Composites, Inc. (Nasdaq: TPIC), today reported financial results for the first quarter ended March 31, 2025. TPI further announced that its Board of Directors has initiated a strategic review of the …
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $100 million Transaction …
BLINK CHARGING ANNOUNCES FIRST QUARTER 2025 RESULTS
GlobeNewswire
·
May 12, 2025
First quarter 2025 total revenues of $20.8 million First quarter 2025 service revenues grew 29.2% to $10.6 million compared to $8.2 million in first quarter of 2024 Gross margin of 35.5% in the first quarter of 2025 During the first quarter the Company …
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
GlobeNewswire
·
May 12, 2025
Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 neuromuscular franchise by YE’26 Phase 3 CAPTIVATE trial …
MidCap Financial Investment Corporation Reports Financial Results for the Quarter Ended March 31, 2025
GlobeNewswire
·
May 12, 2025
Results for the Quarter Ended March 31, 2025 and Other Recent Highlights: Net investment income per share for the quarter was $0.37 Net asset value per share as of the end of the quarter was $14.93, compared to $14.98 as of December 31, 2024, a decrease of …
EloMaas Under Review: The Wild Stallion Pro Herbal Science Breakthrough Formula to Support Sexual Health (StalliOnX)
GlobeNewswire
·
May 12, 2025
New York, May 12, 2025 (GLOBE NEWSWIRE) -- In This Article, You'll Discover: The real reasons behind common male sexual health challenges, including low stamina, reduced drive, and hormonal imbalance How EloMaas featuring Wild Stallion Pro positions itself …
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
On track to report topline data from NMRA-511 in Alzheimer’s disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first …
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
Submitted NDA for Anaphylm™ (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approval Company to host …
Stereotaxis Reports 2025 First Quarter Financial Results
GlobeNewswire
·
May 12, 2025
ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2025. “We’ve …
HighPeak Energy, Inc. Announces First Quarter 2025 Financial and Operating Results
GlobeNewswire
·
May 12, 2025
FORT WORTH, Texas, May 12, 2025 (GLOBE NEWSWIRE) -- HighPeak Energy, Inc. (“HighPeak” or the “Company”) (NASDAQ: HPK) today announced financial and operating results for the quarter ended March 31, 2025, provided an updated 2025 development outlook and …
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors
GlobeNewswire
·
May 12, 2025
JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, …
Xenon Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 – Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD studies on track to initiate mid-year – Results from …
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
GlobeNewswire
·
May 12, 2025
CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) …
Assertio Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
First Quarter Total Net Product Sales of $26.0 Million, In Line with 2025 Outlook Provides Update on Long-Term Business Strategy Designed to Create Sustainable Near-Term Growth and Increased Long-Term Value LAKE FOREST, Ill., May 12, 2025 (GLOBE NEWSWIRE) …
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 study for NDV-01 continues with updates at 6, 9 and 12 …
CompoSecure Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
Operating results in line with expectations Reiterating previously issued full-year 2025 guidance Completed spin-off of Resolute Holdings Management, Inc. (Nasdaq: RHLD) Accounting standards related to the spin-off require the Company to report results …